Patients and the general public are increasingly aware of the benefits of physical activity in reducing the risk of cardiovascular disease (CVD). Yet, many patients (and physicians) find it difficult to fit a dedicated exercise programme into their busy daily schedule. It has been unclear whether increased physical activity related to commuting or transport in general, has the same benefit as longer blocks of leisure time physical activity. Indeed, a recent article in Heart found that occupational physical activity does not have the same benefit as sports physical activity.1 Does this apparent paradox apply to other types of physical activity as well? Or is any activity better than none?

In this issue of Heart, Panter and colleagues2 used data from the UK Biobank database, with almost 360 thousand participants, found that regular commuters who use active modes of transport, compared with those who travel exclusively by car, have a lower risk of both incident (HR 0.89, 95%CI 0.79 to 1.00) and fatal (HR 0.70, 95%CI 0.51 to 0.95) CVD (figure 1). In addition, use of active modes of transport for other activities (not simply going to and from work) was associated with an even lower risk of fatal CVD (HR 0.57, 95%CI 0.39 to 0.85).

Readers should listen to Dr. Jenna Panter discussing these results in more detail in a podcast with Dr. James Rudd (https://soundcloud.com/bmjpodcasts/commuting-and-your-cardiovascular-health?in=bmjpodcasts/sets/heart-podcast).

In the accompanying editorial, Mohanty3 discusses the strengths and limitations of this study, concluding that “the study by Panter et al2 provides the best evidence to date that active (vs passive) non-commute travel is associated with better health outcomes, including among individuals who do not regularly commute. This is an important finding, as many individuals may work remotely, do not work, or only commute occasionally and need additional strategies (eg, active non-commute travel) to incorporate regular physical activity into their routines.” She goes on to ask: “Can the findings of this study be extended beyond urban UK? Caution may be warranted, especially where sociocultural and physical environment differences exist. Access to safe bike or walking paths, weather/seasonal patterns and air quality, among others, may result in different findings.’

Aortic dissection is an uncommon but highly mortal, consequence of hypertension. However, our current standards for risk stratification of adults with aortic dilation are suboptimal, with monitoring and intervention recommendations typically based on a single linear diameter of this complex anatomical structure. In a pair of articles, a research group from Maastricht used 3D computed tomographic imaging of the aorta to provide a more nuanced appreciation of the changes in size and shape of the aorta with normal ageing4 and in patients at risk...
of aortic dissection. These data show that in normal adults the proximal descending aorta undergoes a 2.5X increase in length between age 20 and 80 years, with the maximal curvature of the aortic arch moving more distally with age. (figure 2) In a propensity matched analysis of adults with a Type A dissection, compared with controls, the ascending aorta was longer (78.6±8.8 mm vs 68.9±7.2 mm, P<0.001) as well as more dilated (39.4±5.7 vs 34.4±3.2, P<0.001).

In their editorial, Akin and Nienaber remind us that "aortic diameter is currently the best-evaluated predictor for aortic dissection with specific ‘hinge points’ at which rupture or dissection is increasingly likely to occur. These hinge points are set at around 6 cm for the ascending aorta and 7 cm for the descending aorta, with current recommendations for preventive treatment when the diameter exceeds 5.5 cm regardless of location. For patients with Marfan syndrome or other hereditary conditions, bicuspid aortic valve or family history of aortic dissection, the threshold is set lower at 4.5 cm or 5.0 cm." However, the International Registry of Aortic Dissection showed that "nearly 60% of patients with type A dissection had an aortic diameter <5.5 cm and almost 40% had diameters<5.0 cm, suggesting that aortic diameter alone is an insufficient marker to predict the risk of dissection, and highlighting the need for better predictors." Based on the new data presented by the Maastricht group, they conclude: “both the dynamic diameter and the length of the aorta play an important role in the pathophysiology of aortic dissection. Nevertheless, it should be emphasised that aortic dissection is triggered by multiple other factors.”

Secondary mitral regurgitation (MR) is a common complication of ischaemic heart disease but intervention to reduce the severity of MR in these patients remains controversial. (figure 3) In a meta-analysis of over 1000 patients with secondary (mostly ischaemic) MR, surgical sub-annular repair plus ring annuloplasty was associated with a lower rate of recurrent moderate or greater MR compared with those treated with standard surgical annuloplasty alone (OR 0.27, 95%CI 0.19 to 0.38, P=0.0001). Hung, Gammie and Ailawadi comment that: “Overall, patients with ischaemic MR have significant morbidity and poor prognosis and we need to find innovative, efficacious therapeutic options for these patients. The ideal operation for ischaemic MR is yet to be discovered. It should be a repair (rather than a replacement), result in durable relief of MR and it should be reproducible. We should ‘look under the annulus’ as this may hold the key for an improved therapy for ischaemic MR.”

The Education in Heart article in this issue discusses interventional management of paravalvular leak, summarising diagnosis and management, including medical therapy, transcatheter closure and surgical correction.

Try the Image Challenge question — what is the next best step in management of this young man with cardiac arrest and unusual coronary angiographic findings?

**Competing interests** None declared.

**Patient consent** Not required.

**Provenance and peer review** Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Otto CM. Heart 2018;104:1725–1726.

Heart 2018;104:1725–1726.
doi:10.1136/heartjnl-2018-314133

**REFERENCES**


